NFL Denver Broncos Wide Receiver Eric Decker Teams Up With MusclePharm

Marketwired

DENVER, CO--(Marketwired - Apr 18, 2013) - MusclePharm Corporation (OTCQB: MSLP), a nutritional supplement company focused on active lifestyles, is proud to announce an endorsement deal with Denver Broncos Wide Receiver Eric Decker. As part of the relationship, Decker will represent MusclePharm in a series of advertisements, media appearances, and social media outlets.

Decker had a breakout season in 2012 for the Denver Broncos. In what was Decker's first season having Peyton Manning as his quarterback, he hauled in a career-best 85 catches for 1,064 yards and 13 touchdowns. He was number 20 in the NFL in terms of yards for WRs and his 13 touchdowns were the second most among NFL wide receivers in the 2012 season.

Commenting on the announcement, MusclePharm Founder & CEO Brad Pyatt stated, "Decker not only rose to national prominence in 2012 playing with Peyton Manning, he is also an enormous fan favorite in Denver, home to the MusclePharm headquarters. We are thrilled to have Decker join MusclePharm team."

This is the second NFL player endorsement deal MusclePharm has recently announced. Last month, the Company announced a multi-year endorsement deal with the NFL San Francisco 49ers Super Bowl quarterback Colin Kaepernick.

ABOUT MUSCLEPHARM CORPORATION

MusclePharm is a healthy lifestyle company that develops and manufactures nutritional supplements which address active lifestyles, including muscle building, weight loss and maintaining general fitness through a daily nutritional supplement regimen. The products are formulated through a six-stage research process using the expertise of leading nutritional scientists. MusclePharm's products are sold to consumers in more than 90 countries and available in over 10,500 U.S. retail outlets, including Dick's Sporting Goods, GNC, Vitamin Shoppe and Vitamin World. MusclePharm products also are sold through more than 100 online channels globally, including bodybuilding.com, amazon.com and vitacost.com. MusclePharm also owns FitMiss™, a branded line of fitness supplements which is designed, dosed and formulated specifically for women with active lifestyles. For more information, please visit http://musclepharm.com/.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2011, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Contact:
MusclePharm Company

John H. Bluher
COO
Telephone: 303-618-0902
Email Contact

MusclePharm Investor

The Del Mar Consulting Group, Inc.
Robert B. Prag
President
Telephone: 858-794-9500
Email: Email Contact

or

Alex Partners, LLC
Scott Wilfong
President
Telephone: 425-242-0891
Email: Email Contact
View Comments (0)